Oxford Biomedica (OXB) RNS Announcements

Add to Alert list
Date Time Source Announcement
03 Aug 2021 02:20 PM
RNS
LTIP Option Grant
02 Aug 2021 11:16 AM
RNS
Total Voting Rights
15 Jul 2021 07:00 AM
RNS
Non-Executive Director Appointment
06 Jul 2021 03:10 PM
RNS
Director/PDMR Shareholding
01 Jul 2021 11:35 AM
RNS
Block listing Return
01 Jul 2021 10:43 AM
RNS
Total Voting Rights
24 Jun 2021 01:05 PM
RNS
Directors Dealings / Market Share Purchases
09 Jun 2021 10:36 AM
RNS
Holding(s) in Company
08 Jun 2021 02:32 PM
RNS
Grant of options
01 Jun 2021 10:13 AM
RNS
Total Voting Rights
28 May 2021 07:00 AM
EQS
Oxford Biomedica (OXB): Driving innovation in a...
28 May 2021 07:00 AM
RNS
Block Listing Application
28 May 2021 07:00 AM
RNS
Result of AGM
27 May 2021 07:00 AM
RNS
Board Change
25 May 2021 09:21 AM
RNS
Director/PDMR Shareholding
21 May 2021 12:46 PM
RNS
PDMR Dealing
20 May 2021 11:42 AM
RNS
PDMR Dealings
18 May 2021 07:00 AM
RNS
Oxford Biomedica upgrades financial guidance
18 May 2021 07:00 AM
Oxford Biomedica upgrades financial guidance fo...
10 May 2021 10:54 AM
RNS
Holding(s) in Company
04 May 2021 10:29 AM
RNS
Total Voting Rights
04 May 2021 10:27 AM
RNS
Holdings in Company
27 Apr 2021 02:40 PM
RNS
2020 Annual report and Accounts & AGM Notification
26 Apr 2021 12:32 PM
RNS
Holding(s) in Company
15 Apr 2021 07:00 AM
RNS
Full year results
06 Apr 2021 07:00 AM
RNS
OXB signs Agreement with Boehringer Ingelheim
01 Apr 2021 11:04 AM
RNS
Total Voting Rights
30 Mar 2021 10:22 AM
RNS
Holding(s) in Company
19 Mar 2021 07:01 AM
RNS
Update on Sanofi Collaboration & License Agreement
15 Mar 2021 10:03 AM
RNS
Notice of Preliminary Results
01 Mar 2021 09:36 AM
RNS
Total Voting Rights
26 Feb 2021 10:46 AM
RNS
PDMR Dealings / Market Share sale
05 Feb 2021 01:22 PM
RNS
Holdings in Company
03 Feb 2021 07:00 AM
RNS
Board Changes
01 Feb 2021 09:47 AM
RNS
Total Voting Rights
18 Jan 2021 04:34 PM
RNS
Prime Minister Boris Johnson formally opens Oxbox
04 Jan 2021 02:09 PM
RNS
Block Listing Return
04 Jan 2021 01:41 PM
RNS
Total Voting Rights
30 Dec 2020 09:03 AM
RNS
OXB notes AZ vaccine has been authorised in the UK
01 Dec 2020 12:17 PM
RNS
Director Dealings
01 Dec 2020 09:02 AM
RNS
Total Voting Rights
23 Nov 2020 08:47 AM
RNS
OXB notes AZD1222 met primary efficacy endpoint
23 Nov 2020 07:00 AM
RNS
Non-Executive Director Appointment
09 Nov 2020 07:00 AM
RNS
OXB and PhoreMost enter gene therapy collaboration
02 Nov 2020 09:02 AM
RNS
Total Voting Rights
30 Oct 2020 07:00 AM
RNS
Axovant update on AXO-Lenti-PD and virtual R&D day
23 Oct 2020 10:27 AM
RNS
Director Purchase
12 Oct 2020 05:38 PM
RNS
Holding(s) in Company
06 Oct 2020 12:46 PM
RNS
Axovant update on 2nd cohort of SUNRISE-PD trial
06 Oct 2020 07:00 AM
RNS
OXB receives approval for fourth suite in Oxbox

Oxford Biomedica is a company that specialises in cell and gene therapy, and is a leader in the development of gene-based medicines. They work with pharmaceutical and biotechnology companies to develop and manufacture viral vectors, including lentivirus, adeno-associated virus, and adenoviral vectors.

Headquartered in Oxford, Oxford Biomedica has manufacturing facilities in Oxfordshire, UK, Lyon and Strasbourg, France, and near Boston, MA, US.

Oxford Biomedica share price listed in London under the ticker OXB at 2,570p.

UK 100

Latest directors dealings